$384 Million is the total value of Tamarack Advisers, LP's 32 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ITGR | New | INTEGER HOLDINGS CORPequity | $8,689,000 | – | 115,000 | +100.0% | 2.26% | – |
HMSY | New | HMS HOLDINGS CORPequity | $7,755,000 | – | 225,000 | +100.0% | 2.02% | – |
UTHR | New | UNITED THERAPEUTICS CORPequity | $5,981,000 | – | 75,000 | +100.0% | 1.56% | – |
ICUI | New | ICU MEDICAL INCequity | $5,586,000 | – | 35,000 | +100.0% | 1.46% | – |
PHR | New | PHREESIA INCequity | $4,848,000 | – | 200,000 | +100.0% | 1.26% | – |
OPTN | New | OPTINOSE INCequity | $4,725,000 | – | 675,000 | +100.0% | 1.23% | – |
RDNT | New | RADNET INCequity | $4,667,000 | – | 325,000 | +100.0% | 1.22% | – |
GWPH | New | GW PHARMACEUTICALS -ADRdepository receipt | $2,876,000 | – | 25,000 | +100.0% | 0.75% | – |
New | XLV US 10/18/19 P90put | $540,000 | – | 5,000 | +100.0% | 0.14% | – | |
New | ABT US 10/18/19 P85put | $233,000 | – | 900 | +100.0% | 0.06% | – | |
New | MDRX US 10/18/19 C10call | $208,000 | – | 2,000 | +100.0% | 0.05% | – | |
New | MEDP US 12/20/19 P75put | $116,000 | – | 350 | +100.0% | 0.03% | – | |
New | IWM US 10/18/19 C160call | $110,000 | – | 10,000 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-05
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
VERADIGM ORD | 32 | Q3 2023 | 13.9% |
STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
ATRICURE ORD | 29 | Q3 2023 | 7.6% |
PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
HOLOGIC INC | 17 | Q1 2022 | 6.5% |
SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
Correvio Pharma Corp. | February 15, 2019 | ? | ? |
Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-09 |
13F-HR | 2023-11-16 |
13F-HR | 2023-08-10 |
SC 13D/A | 2023-06-22 |
13F-HR | 2023-05-11 |
13F-HR | 2023-02-13 |
SC 13D/A | 2022-12-01 |
13F-HR | 2022-11-15 |
13F-HR | 2022-08-16 |
13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.